LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Listă Acțiuni・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Închisă

Sector Sănătate

1.35 -1.46

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.33

Maxim

1.41

Indicatori cheie
By Trading Economics
Venit	15M 614K
Vânzări	14M 56M
P/E Medie Sector	26.504 103.001
EPS	-0.08
Marjă de profit	1.093
Angajați	167
EBITDA	14M 11M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+362.96 upside

Statistici piață
By TradingEconomics
Capitalizare de piață	10M 322M
Deschiderea anterioară	2.81
Închiderea anterioară	1.35

Sentimentul știrilor

By Acuity

61%

39%

296 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

1.3 / 1.55 Suport & Rezistență

Akebia Therapeutics Inc Grafic

Știri relevante

28 mar. 2024, 10:30 UTC

Principalele dinamici ale pieței

Akebia Shares Rally Premarket After FDA Approves Vafseo

Comparație

Modificare preț

Akebia Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

362.96% sus

Prognoză pe 12 luni

Medie 6.25 USD 362.96%

Maxim 7.5 USD

Minim 5 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAkebia Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Akebia Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

1.3 / 1.55Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

296 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Akebia Therapeutics Inc

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.